CVS says the new hospital, which will be based at Central Park, Avonmouth, will be custom-built with uniquely designed facilities, state-of-the-art diagnostic tools such as MRI and CT scanners, and a cutting-edge stereotactic linear accelerator for radiotherapy in cancer treatment, the only one of its kind for pets in England.
The hospital, which will open next summer, will employ over 100 people led by a team of Specialist veterinary surgeons and supported by residents, interns and registered veterinary nurses.
Planning permission has been granted for the project, and CVS is now appointing building contractors.
Richard Fairman, CEO of CVS Group, said: "We are extremely excited to be developing this innovative new specialist veterinary hospital in Bristol, providing the best animal care to pet owners across the South West. With state-of-the-art equipment and some of the highest qualified veterinary professionals, we are confident that the site will act as a centre of excellence in the veterinary world, and be a leader in Europe for cancer treatments.
"The new hospital signals our commitment to investing in cutting-edge technology to bring cancer treatment in pets to the next level. It will provide a number of employment opportunities and secure specialist veterinary skills in the Bristol area. We look forward to finalising development plans and opening the doors to pet owners in 2022."
Equibactin vet contains sulfadiazine and trimethoprim, and is indicated for use in the treatment of infections, particularly respiratory tract infections associated with Streptococcus spp. and Staphylococcus aureus; gastrointestinal infections associated with E. coli; urogenital infections associated with beta-hemolytic streptococci; and wound infections and open or drained abscesses associated with Streptococcus spp. and Staphylococcus aureus.
The new product has been designed to provide accurate administration to all sizes of horses or ponies. One syringe provides a complete dose for 600kg bodyweight and is subdivided into 12 markings, to help keep track of dosages.
Dechra Brand Manager Emma Jennings said: "Equibactin vet has a proven antibiotic combination with a synergistic effect2 making it an excellent first line broad spectrum antimicrobial treatment for most Gram positive and negative aerobes.
It can be administered without food which improves the oral bioavailability, offering equine veterinary surgeons a quick and efficient treatment when it comes to targeting these infections that are often experienced in day-to-day practice.
"With its ease of use and three-year shelf life, we anticipate that Equibactin vet will quickly become a popular product when it comes to maintaining equine health."
For more information, visit www.dechra.co.uk/products/equine.
References
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Reference
RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
Nine-year-old Nigel the puma, from Lincolnshire Wildlife Park, was suffering from a deteriorating arthritic condition, which was causing loss of function in his front leg.
His veterinary team consulted an orthopaedic specialist and trialled medical management including steroids and Solensia, but Nigel was unresponsive to treatment.
This led to a severe debilitating limp and pain, leaving a choice between amputation or euthanasia.
Nigel's treatment was funded by donations from visitors to Lincolnshire Wildlife Park, which is a registered charity that was originally established as a sanctuary for parrots in the early 1990s, who raised nearly £5,000 following a fundraising campaign.
The operation took place in a sterile theatre set up in Nigel’s enclosure, where the entire limb was removed, including the scapula.
After an intense five-hour operation, led by Iain Cope, veterinary surgeon and practice owner at Vets4Pets Newmarket, and Shannon Grimwood, veterinary nurse at Vets4Pets Newmarket, Nigel is now on the road to recovery and adapting well to life with three legs.
Iain said: “Nigel’s case was certainly unique and one we haven’t come across before. Working alongside Lincolnshire Wildlife Park and a team of local vets and veterinary nurses, we applied our knowledge of domestic cat amputations to a big one.
“The approach was extremely similar, and the operation ran as smoothly as possible.”
The RCVS has announced that it has accepted the resignation of council member Bob Partridge.
Bob, who had been an elected member of the RCVS Council since July 2006, tendered his resignation for personal reasons.
Peter Robinson will take up the vacated Council position, as he came next in the ballot in the 2013 election.
Pets At Home Vet Group and Dick White Referrals have announced a strategic partnership in order to develop Pets at Home's strategy for providing specialist care.
Pets at Home says it is creating a new divisional structure comprised of the existing First Opinion Division (Vets4Pets and Companion Care joint venture practices) and the new Specialist Division, which comprises Dick White Referrals, Northwest Surgeons, Anderson Moores, and Eye Vet Referrals.
Dick White has been appointed Clinical Director of the new Specialist Division.
Dick will remain as a shareholder in Dick White Referrals. He and three of the Specialist clinicians - Giunio Bruto Cherubini, Federico Corletto and Rob Foale - will retain 24% of the practice.
Sally Hopson, CEO of Pets at Home Vet Group said: "We are delighted to have attracted a colleague of Dick White’s pedigree to join us, not only to help drive the future growth of Dick White Referrals, but also to play a key role in developing our Specialist Division. Professor White is a key figure in the development of the Specialist Veterinary segment; he has trained many of the leading Specialist veterinary practitioners. This is a tremendous step forward for the Vet Group. I’m also very pleased that Professor White and his colleagues have chosen to remain as equity partners in Dick White Referrals."
Dick said: "Forming this strategic partnership provides great opportunities for us to continue to develop Dick White Referrals as a world class referrals centre with a team of leading Veterinary Specialists. I am delighted to be working with a partner that shares our vision for Dick White Referrals and is committed to supporting its future development. Joining the Board of the Specialist Division will allow me to provide clinical leadership and governance across the division, input into the formulation of strategy and support M&A activity and veterinary recruitment."
Instead of conducting major open surgery, Chris Shales, an RCVS and European Specialist in Small Animal Surgery, Andrew Kent, a European Specialist in Internal Medicine, and the cardiology team at Willows are using coil embolization, a minimally invasive technique which they say is far safer and less likely to lead to post-operative complications.
The procedure involves threading tiny coils, via the jugular vein, through the venous system and positioning them in the blood vessel that needs to be closed. The coils encourage the blood to form a clot and so, over time, seal the vein.
Chris said: "This procedure of treating intrahepatic portosystemic shunts is associated with a lower risk of mortality and a lower surgical morbidity rate when comparted to open surgery. The overall outcome of the two approaches is similar in terms of reduction of flow through the shunt vessel.
"Access is gained via a small incision in the neck to allow the team to operate on the liver via the jugular vein using fluoroscopy to visualise the placement of a stent within the vena cava and embolization coils within the abnormal vessel.
"Intrahepatic shunts can be extremely challenging for the surgical team to access with the result that standard, open surgical treatment of these abnormal vessels can risk life-threatening complications and animals can require a significant time to recover."
For more information about shunt surgery at Willows, contact Chris Shales or Small Animal Internal Medicine Specialist Andrew Kent on 0121 712 7070 or email enquiries@willows.uk.net.
Photo: Chris Shales, left, with Andrew Kent, centre, and cardiologist Mike Martin ('pass me a gin and tonic, would you').
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
The Ear Protector sits on the back of the head and hooks onto face mask strings, pulling them backwards and away from the ears, thereby relieving pressure and stopping chafing.
The product was designed by AMufacture's Chief Operating Officer, William Howden, a former Olympic sailor who competed in the 2008 Summer Olympics in Beijing. He said: "Early in the pandemic, it became apparent to us that there was a serious need to address an unresolved problem with face masks – people were really beginning to suffer and were getting distracted from their work."
The Ear Protector is sterilisable in a dishwasher. It is also recyclable when it reaches the end of its life.
The Ear Protectors cost fifty pence each, for orders of two hundred. Contact the company direct for lower volume pricing.
For more information, visit: http://www.theearprotector.com
Lucy and Rosanna have joined the business in hybrid positions as Novice OVs and will do this alongside working in a clinical practice.
The company says this is a significant milestone for the industry, which has relied on overseas talent for many years.
Eville & Jones says it has now developed a compelling proposition for UK new graduates who want to combine OV work with traditional clinical practice, and vets looking for a lifestyle change or a move away from practice, working flexibly in export certification, abattoir work, certification against standards, or small animal vaccination.
Charles Hartwell, chief executive officer of Eville & Jones said: “The team at Eville & Jones has spent two years developing an attractive proposition to encourage UK-educated veterinary surgeons to consider a career in this field, whether combined with traditional clinical practice, or stand alone.
"We wish Lucy and Rosanna the best of luck and hope they become trailblazers for many others to follow in their footsteps.”
Lucy said: “I’m really excited to be starting my career in veterinary public health where, as an OV, you can positively affect the lives of 1000’s of animals."
Rosanna added: “I’m really proud to have joined the veterinary industry this summer; OVs are instrumental in monitoring and safe-guarding animal welfare in a way that many vets don't realise."
Norbrook has announced the launch of Marbodex Aural, the most recent addition to its Otitis Management System for dogs.
Norbrook says the ingredients in Marbodex Aural (marbofloxacin, clotrimazole, dexamethasone) are proven to relieve pain and inflammation quickly, deal with key bacterial and fungal infections effectively and thereby improve pet comfort.
The company says the inclusion of marbofloxacin makes Marbodex Aural an ideal first choice for cases of otitis externa that are:
Marbodex Aural also contains clotrimazole, a broad spectrum antifungal effective against otitis caused by Malassezia pachydermatis, and dexamethasone, a fast acting steroid whose absorption is not increased in inflamed ears.
Marbodex Aural is applied once a day and has two soft nozzles to reduce pain on application and prevent cross-contamination during treatment. It can be used for extended treatment periods of seven to fourteen days when treating persistent infections.
Marbodex Aural is available in all veterinary wholesalers now. For more information about Marbodex and to take advantage of the launch offers, contact your Norbrook Territory Manager or call 01536 741147 for more information.
Reference:
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
The survey found that 51% of cat and dog owners didn't research their pets breed before buying. Of the 22% who then regretted their decision, 31% said it was because they didn’t have enough time to look after the animal, 18% because they turned out to be allergic to the animal, and 16% because they didn’t like their pet’s personality.
Apparently dog owners were more likely to regret their new pet (26%) than cat owners (16%).
Sainsbury’s has therefore launched the Pawfect Match tool, designed to help future pet owners to make informed decisions when choosing the most suitable breed for them. The pet picker asks you a number of questions about your circumstances and makes a number of suggestions based on how you answer.
Sainsbury's campaign is being fronted by Scott Miller MRCVS, who said: "I am saddened to hear that so many pet owners are regretting the animals they have chosen as companions. Dogs and cats come in all shapes and sizes, and have different temperaments. Looking after a pet is a huge commitment so it is important that people undertake adequate research before buying a pet to ensure it is a happy experience."
COMMENT
I tried Sainsbury's pet picker and it recommended a Basset Hound as the first choice. Fair enough. I always think they look like the living embodiment of the word 'hangdog', which is not really my cup of tea. Luckily, the tool makes more than one suggestion. One of the criteria I'd specified was 'quiet and calm', so the second recommendation, a whippet, was fine. But the third caught my eye. A Border Collie. What? Whaaaaaat? Quiet and calm? A Border Collie. Are you having a laugh? I thought Border Collies usually need to be sent to some sort of asylum.
Still, if Sainsbury's tool encourages more people to think harder about their choice, that's no bad thing. But they might like to rethink the Border Collie recommendation.
Kriptazen is supplied with a twist-adjustable and weight-graduated dosing pump which means farmers can administer a precise dose up to 60kg without having to calculate it in ml’s first. Virbac says this will help to reduce the risk of incorrect dosing and toxicity issues.
Virbac’s Technical Product Manager Rosie Naylor said: "We are delighted to bring Kriptazen to the market. The trusted active halofuginone, along with the innovative weight graduated dosing pump, provides practices with added peace of mind when it comes to treatment."
For more information, contact your Virbac Territory Manager.
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
The study looked at the anonymised employment data of 1,642 veterinary nurses working across 418 UK primary-care companion animal veterinary practices at the end of 2020, including both qualified and student nurses.
Of these, 278 (16.9%) nurses resigned from their veterinary practice between 1 January to 31 December 2021.
Career progression was cited as a reason for resigning by 36.7%, compared to 12.9% for personal reasons, 11.9% for better pay, 10.1% for a better work-life balance, 6.8% to relocate, and 3.6% decided not to return after parental leave.
The research also looked at factors associated with lower odds of future nurse resignations.
They included longer employment tenure (p < 0.001) and working at practices with greater property and facilities ratings (p < 0.049).
Head nurses and students were least likely to resign, whereas by comparison, the nurse role was associated with resignations (p = 0.008), adding to the evidence to support nursing career pathways.
The employee engagement metric, eNPS, was also identified as a reliable indicator of nurse retention. reflecting similar findings in other healthcare professions.
Imogen Schofield, Veterinary Statistician and Epidemiologist at CVS, said: “We want to support the whole industry in reducing the number of nurses leaving their roles and the profession.
"Little objective industry data is available on the true reasons behind nurse attrition and we believe this is the first study to outline the risk factors for nurse resignations using practice data, providing an important addition to the evidence-base surrounding this complex topic.
“Reflecting on our research, that was based on data in 2021, we have since seen our attrition rate fall and our employee engagement measure increase as we have focused on developing career pathways, empowering nurses to take on more responsibilities; developing a range of wellbeing programmes, launching a variety of colleague benefits, and significantly investing in our practices.”
I invited Marc Abraham to come and answer some of the concerns raised on VetSurgeon about the ITV Pets Undercover programme.
His PR agency has instead pointed me in the direction of a response he has posted on his own website this morning. Click the link below.
http://www.marcthevet.com/response-to-%e2%80%98pets-undercover%e2%80%99/
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
The study was part of a research project called VetCompass, through which the RVC, in collaboration with Vets Now, collects anonymised clinical information on over 6 million companion animals under veterinary care in the UK.
The study investigated bitches presented with difficulty giving birth (dystocia) from among almost 20,000 bitches attending 50 Vets Now surgeries. Researchers found that out of 20,000 bitches receiving emergency veterinary care, 3.7 per cent of these were treated because of difficulties encountered giving birth.
The most commonly affected breeds were the French Bulldog (15.9 times more likely), Boston Terrier (12.9 times more likely), Chihuahua (10.4 times more likely) and Pug (11.3 times more likely).
Dr Dan O’Neill, a companion animal epidemiologist within the VetCompass Programme, said: "Giving birth in dogs is not always a benign process and our research shows this risk is especially exacerbated in some common brachycephalic and toy breeds. Prospective owners should bear these welfare costs for high risk breeds in mind when choosing their new puppy."
Caroline Kisko, Kennel Club Secretary, said: 'VetCompass' research will not only enable dog breeders to make responsible breeding choices to improve the health of these dogs, it will help to highlight what puppy buyers need to be looking out for if they are intent on owning one of these breeds. If people are choosing a breed simply for its looks and are not going to a reputable breeder, they are likely to face high vet costs and a lifetime of heartache."
This study builds on previous 'purchasing' research by the RVC which found that appearance is the number one reason why owners purchase flat-faced breeds, even though their large, round, wide-set eyes, and flat rounded faces are linked with a variety of inherited diseases.
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
The survey, which takes about 5 minutes (I timed it), is designed to canvas opinion about the priorities for learning and development.
Rich Casey, Junior Vice President of the VMG (pictured right), said: "From marketing to HR to financial planning and all points in between, today’s veterinary leaders require expertise in every aspect of running a successful business.
"We want to create a truly valuable, constructive and evidence-based CPD calendar for next year. Views from those working in the profession will help us to fully understand what good leadership and management look like in the veterinary world and we will then make sure that the programme promotes best practice in these important areas. We thank everyone who takes the time to complete the survey."
The survey can be accessed here: https://www.surveymonkey.co.uk/r/VETCPDPR
Virbac says HCA targets specific affected topical areas with negligible systemic absorption, to provide direct and rapid relief from inflammation and pruritus, delivering significant clinical improvement in atopic cases, both lesion and pruritus scores, after 14 days1.
Cortavance can be applied daily for up to 28 days and included within multimodal treatment plans for prolonged use to control atopy.
Cortavance is presented in a new ergonomic-shaped bottle allowing the user to accurately target the problem area at any angle, with its no-hand-contact spray applicators - 31ml and 76ml sizes.
For further information, contact your local Virbac Territory Manager.
The strange phenomenon was spotted by Veterinary Vision's clinical director Chris Dixon when he examined Dachshund called Margo, which had been referred for the treatment of a corneal ulcer and fungal infection.
Chris said: “I was assessing Margo’s eye and was very surprised to see a face smiling back at me.
"It perhaps doesn't bear quite the same resemblance as the Turin Shroud. Still, I've never seen anything like it before.
"The good news is that it does not appear to have affected her vision at all.”
Apparently the smiling face is still there, even after Chris performed a corneal graft.
Chris added: "I think we can safely say that Margo is a very happy dog, both inside and out!"
Virbac has announced the launch of Carprox Vet, a carprofen-based NSAID indicated for the alleviation of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and cats and for the treatment of chronic pain and inflammation in dogs.
Carprox is presented as a palatable tablet for dogs in three sizes - 20 mg, 50 mg and 100 mg. An injectable 50 mg/ml solution for dogs and cats has also been launched (in bottles of 20ml).
Virbac Marketing Manager for Companion Animals Simon Boulton MRCVS said: "We launched our meloxicam-based solution for acute and chronic pain, Inflacam, in 2013. With the arrival of Carprox Vet, we are now able to offer vets a carprofen-based alternative for added flexibility and choice. We are delighted to add it to our product range and are proud to say that Virbac now offers one of the widest ranges of products for the treatment of small animals in the UK."
Ceva says this is the first time it has advertised Feliway Friends - designed to help cats live together in harmony - on television. It will be rotating the Feliway advert with one explaining the benefits of the Adaptil Calm On-the-Go Collar.
Both advertisements are 30 seconds long and the campaign runs until the end of June. It will target 24.5 million pet owners and will air on all Channel 4 and Channel 4 partner channels, including Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home.
Abigail King, product manager for Feliway and Adaptil at Ceva, said: "Our summer TV advertising campaign will raise awareness of how Feliway Friends and Adaptil Calm On-the-Go Collar can help pets with behavioural issues and drive customers to veterinary practices for further information and to purchase product."
For further information, visit www.feliway.com or www.adaptil.com.